BEGIN:VCALENDAR VERSION:2.0 PRODID:test-knobbe.pantheonsite.io X-WR-TIMEZONE:UTC X-PUBLISHED-TTL:P1W BEGIN:VTIMEZONE TZID:UTC X-LIC-LOCATION:UTC END:VTIMEZONE BEGIN:VEVENT UID:da4d6ee2e4147835f0a4b230be516743 DTSTART;TZID=UTC:20190220T173000 SEQUENCE:0 TRANSP:OPAQUE DTEND;TZID=UTC:20190220T203000 SUMMARY:MIT Enterprise Forum San Diego CLASS:PUBLIC DESCRIPTION:On Wednesday\, February 20\, from 5:30 p.m. - 8:30 p.m.\, Knobb e Martens'\nSan Diego office will be hosting MIT Enterprise Forum and thei r event\,\n\"Hope for Millions: BioFluidica revolutionizes cancer diagnost ics.\"\n\nThis program will give you a look into BioFluidica’s next gene ration\ndiagnostic platform\, providing a non-invasive procedure that can be\napplied to many diseases where there is a need for improved\ndiagnosti cs. The platform has been validated for six different cancer\ntypes\, stro ke\, and infectious diseases. In the cancer field alone\,\nthere is a trem endous need to improve diagnostic capabilities. \n\nBetter cancer detecti on\, and subsequent personalized treatment\,\nprecision medicine\, are key s to improve patient treatment and\noutcomes. Detection of novel biomarker s\, such as Circulating Tumor\nCells\, CTCs\, are leading the way to impro ved diagnostics. In order to\nimprove the survival rate for many cancer d iseases\, the field of\noncology needs better therapies and optimized pers onalized patient\ntreatment. This will require the evolution of better tec hnologies.\nBioFluidica is now delivering these new and improved technolog ies for\nthe analysis of circulating markers\, fullfilling the promise of a true\nliquid biopsy.\n\nFEATURING:\n\nROLF MULLER\, PH.D.\, CEO\, BioFlu idica\n\nKIM KAMDAR\, PH.D.\, Partner\, Domain Associates\n\nPlease click here\n[http://mitefsd.org/event/2019_feb_20/?instance_id=798] to register\ nfor this event.\n X-ALT-DESC;FMTTYPE=text/html:
On Wednesday\, February 20\, from 5:30 p.m. - 8:30 p.m.\, Knobbe Martens' San Diego office will be hosting MIT Enterp rise Forum and their event\, \"Hope for Millions: BioFluidica revolutioniz es cancer diagnostics.\"
\nThis program will give you a look into Bi oFluidica’s next generation diagnostic platform\, providing a non-invasi ve procedure that can be applied to many diseases where there is a need fo r improved diagnostics. The platform has been validated for six different cancer types\, stroke\, and infectious diseases. In the cancer field alone \, there is a tremendous need to improve diagnostic capabilities.
\n< p>Better cancer detection\, and subsequent personalized treatment\, precis ion medicine\, are keys to improve patient treatment and outcomes. Detecti on of novel biomarkers\, such as Circulating Tumor Cells\, CTCs\, are lead ing the way to improved diagnostics. In order to improve the survival rat e for many cancer diseases\, the field of oncology needs better therapies and optimized personalized patient treatment. This will require the evolut ion of better technologies. BioFluidica is now delivering these new and im proved technologies for the analysis of circulating markers\, fullfilling the promise of a true liquid biopsy.\nFeaturing: p>\n
Rolf Muller\, Ph.D.\, CEO\, BioFluidica
\nKim Kamdar\, Ph.D.\, Partner\, Domain Associates
Pl ease click here to register for this event.
\n DTSTAMP:20190920T143506Z END:VEVENT END:VCALENDAR